About 400 reports

  • TOTAL SALES AS REPORTED BY AMGEN AND KHK
  • TOTAL SALES (EX-JAPAN) AS REPORTED BY AMGEN

Hoffmann-La Roche (" Roche" ) to acquire Roche' s rights to filgrastim and pegfilgrastim in approximately ## markets, effective Jan. ##, 2014.

  • Oncology
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • 9.14 DR. REDDY'S LABORATORIES INC.
  • 9.14 DR. REDDY'S LABORATORIES INC.

The company has received approval for tbo-filgrastim (XM## filgrastim).

  • Oncology
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.

TABLE OF CONTENTS (##/ ##) ##.

  • Oncology
  • Therapy
  • World
  • Supply
  • Remicade group
  • 7.11.2 DR. REDDY'S LABORATORIES - MAJOR BIOSIMILARS APPROVED FOR MARKETING
  • Intas Pharmaceuticals major biosimilars approved for marketing are as follows:

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics,...

  • Oncology
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • CURRENT AND FUTURE DIRECTIONS IN THE ONCOLOGY BIOSIMILAR SPACE

In the supportive care space, several filgrastim (Amgen' s Neupogen) biosimilars are already marketed in the ##MM.

  • Oncology
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Cancer Supportive Care Market, Global, Approved Indications for Neulasta, 2017
  • Cancer Supportive Care Market, Global, Approved Indications for Neupogen, 2017

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets Summary Cancer is a disease characterized by abnormal cell growth and uncontrolled proliferation caused by a series of mutations that result in the...

  • Oncology
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Chemotherapy-induced neutropenia

NEUPOGEN (FILGRASTIM) Cancer pain affects a large number of individuals undergoing cancer treatment.

  • Blood Disease
  • Oncology
  • Amgen Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • CANCER IMMUNOTHERAPIES DRUGS MARKET, GLOBAL, GILEAD SCIENCES ANNUAL REVENUE
  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition

PLoS One; ##(##): e## Kotsopoulos J, et al. (2010).

  • Oncology
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Amgen Inc.
  • provides a SWOT analysis of Rolontis.
  • 7.5.2.4 SWOT Analysis

TBO-Filgrastim (Granix).

  • Oncology
  • United States
  • Amgen Inc.
  • BeyondSpring Pharmaceuticals Inc.
  • Helsinn Group

Consequent to the approval of Novartis' Filgrastim biosimilar in the US-the first biosimilar to receive FDA approval-it is expected that the focus on biosimilars will increase in the country.

  • Oncology
  • North America
  • United States
  • World
  • Horizon Discovery
  • Hertraz (Trastuzumab)
  • RITUXIMAB

About Oncology Biosimilars Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting....

  • Oncology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.

One of the commonly used drugs based on G-CSF therapy is NEUPOGEN (filgrastim), which is a human G-CSF produced by recombinant DNA technology.

  • Oncology
  • Amgen Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2018

Gland Surgery; ##(##): ##-## Zhang P, et al. (2016).

  • Oncology
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group
  • TRASTUZUMAB BIOSIMILARS, 2017
  • shows the current status of known trastuzumab biosimilars for HER2-positive breast cancer.

The FDA requires that the biosimilar INN is followed by a four letter suffix, denoting the product manufacturer name, such as filgrastim-sndz in the case of the filgrastim TABLE ##: TRASTUZUMAB BIOSIMILARS, 2017 ##. ##. ## NOMENCLATURE biosimilar by Sandoz.

  • Oncology
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Business Overview
  • Financial Overview

Binocrit (epoetin alfa Zarzio/ Zarxio (filgrastim) Used in therapy area of Hematology. neutropenia after chemotherapy.

  • Biopharmaceutical
  • Hormones
  • Oncology
  • World
  • Market Size

This decrease in white blood cells (neutropenia) can cause complications, and is sometimes treated with drugs like filgrastim.

  • Oncology
  • China
  • Demand
  • Market Size
  • Trade

This decrease in white blood cells (neutropenia) can cause complications, and is sometimes treated with drugs like filgrastim.

  • Oncology
  • China
  • Demand
  • Trade
  • Sanofi-Synthelabo Inc.

Filgrastim i. e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN.

  • Cancer
  • Chemotherapy
  • Oncology
  • Pathology
  • United States

(USA) ##.

  • Oncology
  • Therapy
  • World
  • Market Shares

" Cost to patients is the number one issue [unmet need], number one. "

  • Oncology
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Remicade group
  • 8.2 Table of All Clinical Stage Pipeline Products

Clinical Medicine & Research; ##(##-##): ##-##.

  • Oncology
  • World
  • Market Size
  • Bristol-Myers Squibb Company
  • Novartis AG

Neupogen (filgrastim) ##.

  • Oncology
  • United States
  • Demand
  • AstraZeneca PLC
  • Roche Group

Neupogen (filgrastim) ##.

  • Oncology
  • Therapy
  • United States
  • Demand
  • Amgen Inc.

Neupogen (filgrastim) ##.

  • Chemotherapy
  • Oncology
  • Therapy
  • North America
  • United States

IN MARCH 2015, THE US FDA APPROVED THE FIRST BIOSIMILAR, ZARXIO (FILGRASTIM BIOSIMILAR), AND IS CURRENTLY IN THE PROCESS OF FORMALIZING INDUSTRY GUIDANCE FOR BIOSIMILAR DEVELOPMENT (FDA, PRESS RELEASE, MARCH ##, 2015).

  • Oncology
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novartis AG

NEUPOGEN (FILGRASTIM) ##.

  • Oncology
  • North America
  • United States
  • Demand
  • Roche Group

Neupogen (filgrastim) ##.

  • Oncology
  • North America
  • United States
  • Biocon Limited
  • Roche Group

Neupogen (filgrastim) ##.

  • Oncology
  • United States
  • AstraZeneca PLC
  • Pfizer Inc.
  • Roche Group

PLoS One; ##(##): ##-##.

  • Oncology
  • World
  • Celgene Corporation
  • Novartis AG
  • Pfizer Inc.

Neupogen (filgrastim) ##.

  • Leukemia
  • Oncology
  • United States
  • Gilead Sciences, Inc.
  • Roche Group